Pfizer's GLP-1 Drug May Challenge Novo Nordisk and Eli Lilly's Market Dominance
Pfizer is advancing its GLP-1 drug, PF-08653944, which is showing strong results in Phase 2b trials, potentially challenging the market dominance of Novo Nordisk and Eli Lilly in the weight-loss drug sector. The growing anti-obesity drug market, expected to expand at a 25% annual rate through 2035, is attracting new competitors like Pfizer.
Topics: Eli Lilly GLP-1 drugs Novo Nordisk Pfizer pharmaceutical industry weight-loss drugs